|Bid||0.0000 x 1300|
|Ask||0.0000 x 1200|
|Day's Range||3.5945 - 3.7484|
|52 Week Range||3.2500 - 6.8600|
|Beta (3Y Monthly)||1.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Anixa Biosciences, Inc. (NASDAQ:ANIX) continues its loss-making streak, announcing negative earnings for its latest...
It is not uncommon to see companies perform well in the years after insiders buy shares. The flip side of that is that...
Anixa Biosciences Inc (NASDAQ: ANIX) shares were trading higher Wednesday after the company announced a licensing agreement with the Cleveland Clinic for breast cancer vaccine technology. Cleveland Clinic researcher Dr. Vincent Tuohy said in a statement that he has identified a specific protein that is "retired" from service after a woman has given birth, but reappears in many forms of breast cancer, especially TNBC. Tuohy and Cleveland Clinic were awarded a $6.2-million grant from the Department of Defense in November 2017 to provide funding for the completion of pre-clinical studies as well as the completion of two Phase 1 clinical studies to test the vaccine in patients.
Every investor in Anixa Biosciences, Inc. (NASDAQ:ANIX) should be aware of the most powerful shareholder groups. Large...
If you're interested in Anixa Biosciences, Inc. (NASDAQ:ANIX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Anixa Biosciences, Inc.'s (NASDAQ:ANIX) latest earnings announcement Read More...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...